Glioma Market Report and Forecast 2025-2034
Description
The glioma market was valued at USD 1.00 Billion in 2024 driven by the incidence of increasing glioma prevalence across the 8 major markets. The market is expected to grow at a CAGR of 3.22% during the forecast period 2025-2034 and attain a market value of USD 1.37 Billion by 2034.
Glioma Market Overview
Gliomas are tumors that begin in the brain or spinal cord, consisting of cells that look like normal glial cells providing aid to nerve activity. As glioma grows, it forms a mass that can cause compression on brain or spinal cord tissue, leading to symptoms specific to the affected area. Different types of gliomas are present, with some growing slowly and not considered cancerous, and others, known as malignant gliomas, spreading quickly to neighboring healthy tissue. There are four different grades of differentiation that gliomas can exhibit. Grade I gliomas are the most differentiated and least malignant, whereas Grade IV tumors are the least differentiated and most malignant. The type of glioma determines the seriousness of the condition and the appropriate course of treatment.
Gliomas may progress to brain tumors, penetrating and harming healthy tissue. In general, tumors called gliomas impact glial cells that support nerves and can cause issues as they expand and impact nearby tissues. The process of diagnosing glioma includes neurological tests, angiograms, MRI scans, CT scans, and surgical biopsies. Seizures, headaches, mood changes, and difficulty walking lead the patient to see a general practitioner, who then recommends a visit to a neuro-oncologist.
Glioma Market Growth Drivers
Impact of Increasing Glioma Prevalence on Market Dynamics
The increasing prevalence of glioma is driving demand for advanced glioma treatments. Factors such as aging populations, genetic mutations, and environmental risks like radiation contribute to the rising glioma cases. Approximately 80,000 new instances of primary brain tumors are diagnosed annually in the United States, with around 25% being gliomas. Around 12,000 cases of glioblastomas are diagnosed annually. Advanced imaging technologies and early detection efforts have improved identification rates, while ongoing research initiatives enhance understanding and reporting of glioma incidences. To address this growing concern, healthcare providers are focusing on early detection through enhanced screening and molecular diagnostics, while pharmaceutical companies and medical device manufacturers are developing targeted therapies and improving imaging technologies. Collaboration among advocacy groups, healthcare organizations, and research institutions aims to drive continuous advancements in the glioma market.
Advancements in Treatment to Address Rising Glioma Market Demand
Advancements in glioma treatment like minimally invasive surgeries and intraoperative imaging tools, lower surgical dangers and enhanced accuracy are rising in the market. Focused treatments such as molecularly targeted drugs and immunotherapies provide tailored care depending on genetic and molecular tumor characteristics. Advancements in radiation therapy, such as stereotactic radiosurgery and proton therapy, have enhanced treatment by precisely targeting tumors with high doses of radiation. Furthermore, improvements in chemotherapy have increased effectiveness while reducing overall side effects.
Glioma Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Advancements in Diagnostic Technologies
MRI, perfusion imaging, and spectroscopy offer in-depth data for precise tumor diagnosis and visualization. Molecular diagnostics help identify genetic mutations and biomarkers, which inform personalized treatment plans. Advancements in biopsies decrease invasiveness and enhance precision in identifying tumor traits. Artificial intelligence in diagnostic processes improves precision and effectiveness by forecasting tumor advancement and aiding in clinical decision-making. In general, these technologies represent a revolutionary era in glioma diagnostics, focusing on early identification, tailored therapy, and better patient results.
Rising Emphasis on Research
Advancements in glioma research are expected to improve the understanding of the disease's biology, leading to new treatment targets and strategies. Pharmaceutical companies are investing in developing specialized drugs for glioma patients. Research also enhances diagnostic capabilities, allowing for earlier detection and personalized treatment plans. Collaboration among academia, industry, and healthcare providers promotes knowledge and enables sharing of best practices in managing glioma.
Awareness and Education
Raising knowledge and promoting education on gliomas is crucial for generating interest in treatments. Educational initiatives aimed at healthcare professionals and the public can lead to early detection and intervention. Patients who are knowledgeable tend to seek specialized care and take part in treatment decisions more often.
Government and Non-Governmental Initiatives
Government organizations are providing funding for glioma research to enhance treatment, diagnostics, and patient care, leading to improved accessibility to public healthcare and better outcomes. The partnership among governments, NGOs, and pharmaceutical corporations speeds up clinical trials and authorizations, broadening treatment choices and enhancing worldwide patient care.
Glioma Market Segmentation
The EMR’s report titled “Glioma Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type
Market Segmentation Based on Treatment Type to Witness Growth
The market segmentation based on treatment type includes chemotherapy, radiation therapy, targeted drug therapy and others. Chemotherapy uses potent drugs to kill cancer cells or prevent their growth. It is given orally or intravenously, circulating throughout the body. It is expected to hold a significant market share in the forecast period. Radiation therapy utilizes high-energy rays to kill cancer cells in a targeted area. It is frequently used in glioma treatment to shrink difficult-to-remove tumors or treat residual cells post-surgery, focusing on specific tumor locations.
Glioma Market Analysis by Region
Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, and Spain), the United Kingdom, Japan, and India. The United States is expected to dominate the glioma market due to its advanced healthcare services and high prevalence of glioma. Big pharmaceutical companies and robust regulations support market expansion in the region. Increased awareness is improving diagnostic technologies, and a growing elderly population is fueling the need for glioma treatments, resulting in market demand.
The EU-4 and United Kingdom market is also experiencing robust growth because of well-developed healthcare systems and research programs that push forward innovations in treating glioma. Partnerships between academic institutions and pharmaceutical companies are resulting in the development of novel treatments. The market in Japan and India is also experiencing significant growth. The glioma market in Japan is boosted by cutting-edge healthcare technologies and personalized medicine.
Leading Players in the Glioma Market
The key features of the market report include patent analysis, clinical trials analysis, grant analysis, funding, and investment analysis as well as strategic initiatives by the leading players. The major companies in the market are as follows:
Denovo Biopharma LLC
Denovo Biopharma, established in 2012, specializes in creating precision medicines driven by biomarkers through a technology platform that enables biomarker discovery and assists in drug development. Their fundamental technology allows for the identification of new genomic biomarkers in different areas of therapy. In July 2023, the FDA approved a Phase 2 trial of DB107 for the treatment of high-grade glioma.
AIVITA Biomedical, Inc.
AIVITA Biomedical, established in 2016, specializes in creating personalized vaccines for pathogens and tumor-initiating cells. Their system applies stem cell knowledge for the secure and cost-effective production of market goods and treatments.
Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics, Inc., a pharmaceutical company established in 1996 in Maryland, USA, is dedicated to creating tailored immunotherapy products for treating cancer. Their flagship product, DCVax®-L, is focused on glioblastoma, known as the most aggressive type of brain cancer. The company has finished Phase III trials, released findings, and requested UK commercial approval. DCVax®-Direct has been created for solid tumors as well.
AstraZeneca
AstraZeneca, established in 1999, is a pharmaceutical company based in Britain and Sweden. The company is based in Cambridge, England, and offers a range of products for conditions such as oncology, cardiovascular, and respiratory illnesses. In April 2024, the outcomes of AZD1390 were encouraging for individuals with Glioblastoma.
Other players in the market include Bayer AG, Bristol-Myers Squibb Company, Chimerix, CNS Pharmaceuticals, Inc., ERC SA., Immunomic Therapeutics, Inc., Laminar Pharmaceuticals, S.A., Medicenna Therapeutics, MimiVax, Inc., and VBL Therapeutics.
Key Questions Answered in the Glioma Market Report
Glioma Market Overview
Gliomas are tumors that begin in the brain or spinal cord, consisting of cells that look like normal glial cells providing aid to nerve activity. As glioma grows, it forms a mass that can cause compression on brain or spinal cord tissue, leading to symptoms specific to the affected area. Different types of gliomas are present, with some growing slowly and not considered cancerous, and others, known as malignant gliomas, spreading quickly to neighboring healthy tissue. There are four different grades of differentiation that gliomas can exhibit. Grade I gliomas are the most differentiated and least malignant, whereas Grade IV tumors are the least differentiated and most malignant. The type of glioma determines the seriousness of the condition and the appropriate course of treatment.
Gliomas may progress to brain tumors, penetrating and harming healthy tissue. In general, tumors called gliomas impact glial cells that support nerves and can cause issues as they expand and impact nearby tissues. The process of diagnosing glioma includes neurological tests, angiograms, MRI scans, CT scans, and surgical biopsies. Seizures, headaches, mood changes, and difficulty walking lead the patient to see a general practitioner, who then recommends a visit to a neuro-oncologist.
Glioma Market Growth Drivers
Impact of Increasing Glioma Prevalence on Market Dynamics
The increasing prevalence of glioma is driving demand for advanced glioma treatments. Factors such as aging populations, genetic mutations, and environmental risks like radiation contribute to the rising glioma cases. Approximately 80,000 new instances of primary brain tumors are diagnosed annually in the United States, with around 25% being gliomas. Around 12,000 cases of glioblastomas are diagnosed annually. Advanced imaging technologies and early detection efforts have improved identification rates, while ongoing research initiatives enhance understanding and reporting of glioma incidences. To address this growing concern, healthcare providers are focusing on early detection through enhanced screening and molecular diagnostics, while pharmaceutical companies and medical device manufacturers are developing targeted therapies and improving imaging technologies. Collaboration among advocacy groups, healthcare organizations, and research institutions aims to drive continuous advancements in the glioma market.
Advancements in Treatment to Address Rising Glioma Market Demand
Advancements in glioma treatment like minimally invasive surgeries and intraoperative imaging tools, lower surgical dangers and enhanced accuracy are rising in the market. Focused treatments such as molecularly targeted drugs and immunotherapies provide tailored care depending on genetic and molecular tumor characteristics. Advancements in radiation therapy, such as stereotactic radiosurgery and proton therapy, have enhanced treatment by precisely targeting tumors with high doses of radiation. Furthermore, improvements in chemotherapy have increased effectiveness while reducing overall side effects.
Glioma Market Trends
The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:
Advancements in Diagnostic Technologies
MRI, perfusion imaging, and spectroscopy offer in-depth data for precise tumor diagnosis and visualization. Molecular diagnostics help identify genetic mutations and biomarkers, which inform personalized treatment plans. Advancements in biopsies decrease invasiveness and enhance precision in identifying tumor traits. Artificial intelligence in diagnostic processes improves precision and effectiveness by forecasting tumor advancement and aiding in clinical decision-making. In general, these technologies represent a revolutionary era in glioma diagnostics, focusing on early identification, tailored therapy, and better patient results.
Rising Emphasis on Research
Advancements in glioma research are expected to improve the understanding of the disease's biology, leading to new treatment targets and strategies. Pharmaceutical companies are investing in developing specialized drugs for glioma patients. Research also enhances diagnostic capabilities, allowing for earlier detection and personalized treatment plans. Collaboration among academia, industry, and healthcare providers promotes knowledge and enables sharing of best practices in managing glioma.
Awareness and Education
Raising knowledge and promoting education on gliomas is crucial for generating interest in treatments. Educational initiatives aimed at healthcare professionals and the public can lead to early detection and intervention. Patients who are knowledgeable tend to seek specialized care and take part in treatment decisions more often.
Government and Non-Governmental Initiatives
Government organizations are providing funding for glioma research to enhance treatment, diagnostics, and patient care, leading to improved accessibility to public healthcare and better outcomes. The partnership among governments, NGOs, and pharmaceutical corporations speeds up clinical trials and authorizations, broadening treatment choices and enhancing worldwide patient care.
Glioma Market Segmentation
The EMR’s report titled “Glioma Market Report and Forecast 2025-2034” offers a detailed analysis of the market based on the following segments:
Market Breakup by Treatment Type
- Chemotherapy
- Radiation Therapy
- Targeted Drug Therapy
- Others
- Low Grade
- High Grade
- Hospital/Clinics
- Ambulatory Surgical Centers
- Cancer Centers
- Others
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
- India
Market Segmentation Based on Treatment Type to Witness Growth
The market segmentation based on treatment type includes chemotherapy, radiation therapy, targeted drug therapy and others. Chemotherapy uses potent drugs to kill cancer cells or prevent their growth. It is given orally or intravenously, circulating throughout the body. It is expected to hold a significant market share in the forecast period. Radiation therapy utilizes high-energy rays to kill cancer cells in a targeted area. It is frequently used in glioma treatment to shrink difficult-to-remove tumors or treat residual cells post-surgery, focusing on specific tumor locations.
Glioma Market Analysis by Region
Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, and Spain), the United Kingdom, Japan, and India. The United States is expected to dominate the glioma market due to its advanced healthcare services and high prevalence of glioma. Big pharmaceutical companies and robust regulations support market expansion in the region. Increased awareness is improving diagnostic technologies, and a growing elderly population is fueling the need for glioma treatments, resulting in market demand.
The EU-4 and United Kingdom market is also experiencing robust growth because of well-developed healthcare systems and research programs that push forward innovations in treating glioma. Partnerships between academic institutions and pharmaceutical companies are resulting in the development of novel treatments. The market in Japan and India is also experiencing significant growth. The glioma market in Japan is boosted by cutting-edge healthcare technologies and personalized medicine.
Leading Players in the Glioma Market
The key features of the market report include patent analysis, clinical trials analysis, grant analysis, funding, and investment analysis as well as strategic initiatives by the leading players. The major companies in the market are as follows:
Denovo Biopharma LLC
Denovo Biopharma, established in 2012, specializes in creating precision medicines driven by biomarkers through a technology platform that enables biomarker discovery and assists in drug development. Their fundamental technology allows for the identification of new genomic biomarkers in different areas of therapy. In July 2023, the FDA approved a Phase 2 trial of DB107 for the treatment of high-grade glioma.
AIVITA Biomedical, Inc.
AIVITA Biomedical, established in 2016, specializes in creating personalized vaccines for pathogens and tumor-initiating cells. Their system applies stem cell knowledge for the secure and cost-effective production of market goods and treatments.
Northwest Biotherapeutics, Inc.
Northwest Biotherapeutics, Inc., a pharmaceutical company established in 1996 in Maryland, USA, is dedicated to creating tailored immunotherapy products for treating cancer. Their flagship product, DCVax®-L, is focused on glioblastoma, known as the most aggressive type of brain cancer. The company has finished Phase III trials, released findings, and requested UK commercial approval. DCVax®-Direct has been created for solid tumors as well.
AstraZeneca
AstraZeneca, established in 1999, is a pharmaceutical company based in Britain and Sweden. The company is based in Cambridge, England, and offers a range of products for conditions such as oncology, cardiovascular, and respiratory illnesses. In April 2024, the outcomes of AZD1390 were encouraging for individuals with Glioblastoma.
Other players in the market include Bayer AG, Bristol-Myers Squibb Company, Chimerix, CNS Pharmaceuticals, Inc., ERC SA., Immunomic Therapeutics, Inc., Laminar Pharmaceuticals, S.A., Medicenna Therapeutics, MimiVax, Inc., and VBL Therapeutics.
Key Questions Answered in the Glioma Market Report
- What was the glioma market value in 2024?
- What is the glioma market forecast outlook for 2025-2034?
- What are the regional markets covered in the EMR report?
- What is market segmentation based on treatment type?
- What is market segmentation based on type?
- What are the major end users in the market?
- What are the major factors aiding the glioma market demand?
- How has the market performed so far and how is it anticipated to perform in the coming years?
- What are the major drivers, opportunities, and restraints in the market?
- What are the major trends influencing the market?
- Which treatment type will dominate the market?
- Which regional market is expected to dominate the market share in the forecast period?
- Which country is likely to experience elevated growth during the forecast period?
- Who are the key players involved in the glioma market?
- What are the current unmet needs and challenges in the market?
- How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?
Table of Contents
400 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Glioma Market Overview – 8 Major Markets
- 3.1 Glioma Market Historical Value (2018-2024)
- 3.2 Glioma Market Forecast Value (2025-2034)
- 4 Vendor Positioning Analysis
- 4.1 Key Vendors
- 4.2 Prospective Leaders
- 4.3 Niche Leaders
- 4.4 Disruptors
- 5 Glioma Overview
- 5.1 Guidelines and Stages
- 5.2 Pathophysiology
- 5.3 Screening and Diagnosis
- 5.4 Treatment Pathway
- 6 Patient Profile
- 6.1 Patient Profile Overview
- 6.2 Patient Psychology and Emotional Impact Factors
- 6.3 Risk Assessment and Treatment Success Rate
- 7 Glioma Market - Epidemiology Scenario and Forecast – 8 Major Markets
- 7.1 8MM Epidemiology Scenario Overview (2018-2034)
- 7.1.1 Prevalence, by Country
- 7.1.1.1 United States
- 7.1.1.2 United Kingdom
- 7.1.1.3 EU4
- 7.1.1.4 India
- 7.1.1.5 Japan
- 7.1.2 Diagnosed Cases, by Country
- 7.1.2.1 United States
- 7.1.2.2 United Kingdom
- 7.1.2.3 EU4
- 7.1.2.4 India
- 7.1.2.5 Japan
- 7.1.3 Treatment seeking rate, by Country
- 7.1.3.1 United States
- 7.1.3.2 United Kingdom
- 7.1.3.3 EU4
- 7.1.3.4 India
- 7.1.3.5 Japan
- 8 Glioma Market Landscape – 8 Major Markets
- 8.1 Glioma Market: Developers Landscape
- 8.1.1 Analysis by Year of Establishment
- 8.1.2 Analysis by Company Size
- 8.1.3 Analysis by Region
- 8.2 Glioma Market: Product Landscape
- 8.2.1 Analysis by Treatment Type
- 9 Glioma Market Challenges and Unmet Needs
- 9.1 Treatment Pathway Challenges
- 9.2 Compliance and Drop-Out Analysis
- 9.3 Awareness and Prevention Gaps
- 10 Cost of Treatment
- 11 Glioma Market Dynamics
- 11.1 Market Drivers and Constraints
- 11.2 SWOT Analysis
- 11.2.1 Strengths
- 11.2.2 Weaknesses
- 11.2.3 Opportunities
- 11.2.4 Threats
- 11.3 PESTEL Analysis
- 11.3.1 Political
- 11.3.2 Economic
- 11.3.3 Social
- 11.3.4 Technological
- 11.3.5 Legal
- 11.3.6 Environment
- 11.4 Porter’s Five Forces Model
- 11.4.1 Bargaining Power of Suppliers
- 11.4.2 Bargaining Power of Buyers
- 11.4.3 Threat of New Entrants
- 11.4.4 Threat of Substitutes
- 11.4.5 Degree of Rivalry
- 11.5 Key Demand Indicators
- 11.6 Key Price Indicators
- 11.7 Industry Events, Initiatives, and Trends
- 11.8 Value Chain Analysis
- 12 Glioma Market Segmentation (218-2034) - 8 Major Markets
- 12.1 Glioma Market (2018-2034) by Treatment Type
- 12.1.1 Market Overview
- 12.1.2 Chemotherapy
- 12.1.3 Radiation Therapy
- 12.1.4 Targeted Drug Therapy
- 12.1.5 Others
- 12.2 Glioma Market (2018-2034) by Type
- 12.2.1 Market Overview
- 12.2.2 Low Grade
- 12.2.3 High Grade
- 12.3 Glioma Market (2018-2034) by End User
- 12.3.1 Market Overview
- 12.3.2 Hospital/Clinics
- 12.3.3 Ambulatory Surgical Centers
- 12.3.4 Cancer Centers
- 12.3.5 Others
- 12.4 Glioma Market (2018-2034) by Region
- 12.4.1 Market Overview
- 12.4.2 United States
- 12.4.3 EU-4 and the United Kingdom
- 12.4.3.1 Germany
- 12.4.3.2 France
- 12.4.3.3 Italy
- 12.4.3.4 Spain
- 12.4.3.5 United Kingdom
- 12.4.4 Japan
- 12.4.5 India
- 13 United States Glioma Market (218-2034)
- 13.1 United States Glioma Market Historical Value (2018-2024)
- 13.2 United States Glioma Market Forecast Value (2025-2034)
- 13.3 United States Glioma Market (2018-2034) by Treatment Type
- 13.3.1 Market Overview
- 13.3.2 Chemotherapy
- 13.3.3 Radiation Therapy
- 13.3.4 Targeted Drug Therapy
- 13.3.5 Others
- 13.4 United States Glioma Market (2018-2034) by End User
- 13.4.1 Market Overview
- 13.4.2 Hospital/Clinics
- 13.4.3 Ambulatory Surgical Centers
- 13.4.4 Cancer Centers
- 13.4.5 Others
- 14 EU-4 and United Kingdom Glioma Market (218-2034)
- 14.1 EU-4 and United Kingdom Glioma Market Historical Value (2018-2024)
- 14.2 EU-4 and United Kingdom Glioma Market Forecast Value (2025-2034)
- 14.3 EU-4 and United Kingdom Glioma Market (2018-2034) by Treatment Type
- 14.3.1 Market Overview
- 14.3.2 Chemotherapy
- 14.3.3 Radiation Therapy
- 14.3.4 Targeted Drug Therapy
- 14.3.5 Others
- 14.4 EU-4 and United Kingdom Glioma Market (2018-2034) by End User
- 14.4.1 Market Overview
- 14.4.2 Hospital/Clinics
- 14.4.3 Ambulatory Surgical Centers
- 14.4.4 Cancer Centers
- 14.4.5 Others
- 15 Japan Glioma Market
- 15.1 Japan Glioma Market Historical Value (2018-2024)
- 15.2 Japan Glioma Market Forecast Value (2025-2034)
- 15.3 Japan Glioma Market (2018-2034) by Treatment Type
- 15.3.1 Market Overview
- 15.3.2 Chemotherapy
- 15.3.3 Radiation Therapy
- 15.3.4 Targeted Drug Therapy
- 15.3.5 Others
- 15.4 Japan Glioma Market (2018-2034) by End User
- 15.4.1 Market Overview
- 15.4.2 Hospital/Clinics
- 15.4.3 Ambulatory Surgical Centers
- 15.4.4 Cancer Centers
- 15.4.5 Others
- 16 India Glioma Market
- 16.1 India Glioma Market (2018-2034) Historical Value (2018-2024)
- 16.2 India Glioma Market (2018-2034) Forecast Value (2025-2034)
- 16.3 India Glioma Market (2018-2034) by Treatment Type
- 16.3.1 Market Overview
- 16.3.2 Chemotherapy
- 16.3.3 Radiation Therapy
- 16.3.4 Targeted Drug Therapy
- 16.3.5 Others
- 16.4 India Glioma Market (2018-2034) by End User
- 16.4.1 Market Overview
- 16.4.2 Hospital/Clinics
- 16.4.3 Ambulatory Surgical Centers
- 16.4.4 Cancer Centers
- 16.4.5 Others
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.2 US FDA
- 17.3 EU EMA
- 17.4 Japan PMDA
- 17.5 India CDSCO
- 17.6 Others
- 18 Patent Analysis
- 18.1 Analysis by Type of Patent
- 18.2 Analysis by Publication Year
- 18.3 Analysis by Issuing Authority
- 18.4 Analysis by Patent Age
- 18.5 Analysis by CPC Analysis
- 18.6 Analysis by Patent Valuation
- 19 Clinical Trials Analysis
- 19.1 Analysis by Trial Registration Year
- 19.2 Analysis by Trial Status
- 19.3 Analysis by Trial Phase
- 19.4 Analysis by Therapeutic Area
- 19.5 Analysis by Geography
- 20 Grants Analysis
- 20.1 Analysis by Year
- 20.2 Analysis by Amount Awarded
- 20.3 Analysis by Issuing Authority
- 20.4 Analysis by Grant Application
- 20.5 Analysis by Funding Institute
- 20.6 Analysis by NIH Departments
- 20.7 Analysis by Recipient Organization
- 21 Funding and Investment Analysis
- 21.1 Analysis by Funding Instances
- 21.2 Analysis by Type of Funding
- 21.3 Analysis by Funding Amount
- 21.4 Analysis by Leading Players
- 21.5 Analysis by Leading Investors
- 21.6 Analysis by Geography
- 22 Strategic Initiatives
- 22.1 Analysis by Partnership Instances
- 22.2 Analysis by Type of Partnership
- 22.3 Analysis by Leading Players
- 22.4 Analysis by Geography
- 23 Supplier Landscape
- 23.1 Market Share by Top 5 Companies
- 23.2 Bayer AG
- 23.2.1 Financial Analysis
- 23.2.2 Product Portfolio
- 23.2.3 Demographic Reach and Achievements
- 23.2.4 Company News and Development
- 23.2.5 Certifications
- 23.3 Chimerix
- 23.3.1 Financial Analysis
- 23.3.2 Product Portfolio
- 23.3.3 Demographic Reach and Achievements
- 23.3.4 Company News and Development
- 23.3.5 Certifications
- 23.4 AIVITA Biomedical Inc.
- 23.4.1 Financial Analysis
- 23.4.2 Product Portfolio
- 23.4.3 Demographic Reach and Achievements
- 23.4.4 Company News and Development
- 23.4.5 Certifications
- 23.5 Denovo BioPharma LLC
- 23.5.1 Financial Analysis
- 23.5.2 Product Portfolio
- 23.5.3 Demographic Reach and Achievements
- 23.5.4 Company News and Development
- 23.5.5 Certifications
- 23.6 Northwest Biotherapeutics Inc.
- 23.6.1 Financial Analysis
- 23.6.2 Product Portfolio
- 23.6.3 Demographic Reach and Achievements
- 23.6.4 Company News and Development
- 23.6.5 Certifications
- 23.7 VBL Therapeutics
- 23.7.1 Financial Analysis
- 23.7.2 Product Portfolio
- 23.7.3 Demographic Reach and Achievements
- 23.7.4 Company News and Development
- 23.7.5 Certifications
- 23.8 Laminar Pharmaceuticals, S.A.
- 23.8.1 Financial Analysis
- 23.8.2 Product Portfolio
- 23.8.3 Demographic Reach and Achievements
- 23.8.4 Company News and Development
- 23.8.5 Certifications
- 23.9 AstraZeneca
- 23.9.1 Financial Analysis
- 23.9.2 Product Portfolio
- 23.9.3 Demographic Reach and Achievements
- 23.9.4 Company News and Development
- 23.9.5 Certifications
- 23.10 Immunomic Therapeutics
- 23.10.1 Financial Analysis
- 23.10.2 Product Portfolio
- 23.10.3 Demographic Reach and Achievements
- 23.10.4 Company News and Development
- 23.10.5 Certifications
- 23.11 MimiVax Inc.
- 23.11.1 Financial Analysis
- 23.11.2 Product Portfolio
- 23.11.3 Demographic Reach and Achievements
- 23.11.4 Company News and Development
- 23.11.5 Certifications
- 23.12 CNS Pharmaceuticals Inc.
- 23.12.1 Financial Analysis
- 23.12.2 Product Portfolio
- 23.12.3 Demographic Reach and Achievements
- 23.12.4 Company News and Development
- 23.12.5 Certifications
- 23.13 ERC SA.
- 23.13.1 Financial Analysis
- 23.13.2 Product Portfolio
- 23.13.3 Demographic Reach and Achievements
- 23.13.4 Company News and Development
- 23.13.5 Certifications
- 23.14 Bristol-Myers Squibb Company
- 23.14.1 Financial Analysis
- 23.14.2 Product Portfolio
- 23.14.3 Demographic Reach and Achievements
- 23.14.4 Company News and Development
- 23.14.5 Certifications
- 23.15 Medicenna Therapeutics
- 23.15.1 Financial Analysis
- 23.15.2 Product Portfolio
- 23.15.3 Demographic Reach and Achievements
- 23.15.4 Company News and Development
- 23.15.5 Certifications
- 24 Glioma Treatment Drugs - Distribution Model (Additional Insight)
- 24.1 Overview
- 24.2 Potential Distributors
- 24.3 Key Parameters for Distribution Partner Assessment
- 25 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 26 Payment Methods (Additional Insight)
- 26.1 Government Funded
- 26.2 Private Insurance
- 26.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
